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Specific binding proteins (BPS) to somatomedin/insulin-like 
growth factors (Sm/lGFs) have been identified in conditioned 
media from a variety of cells in culture. By affinity cross- 
linking using disuccinimidyl suberate, we have covalently 
cross-linked radiolabeled somatomedin-C/insulin-like growth 
factor I (Sm-C/IGF I), insulin-like growth factor II (IGF II) and 
insulin to BPS in conditioned medium (CM) from cultured 
astroglial cells derived from cerebral cortices of neonatal 
rats. Two species of radiolabeled Sm/lGF BP complexes of 
40,000 Da (40K) and 45K were identified. Competition with 
unlabeled Sm-C/IGF I and IGF II demonstrated that the BPS 
in each complex have similar affinities for Sm-C/IGF I and 
IGF II. The BP in the 45K complex was about L-fold more 
sensitive to competition with unlabeled Sm/lGFs than the BP 
in the 40K complex, suggesting that it either has a higher 
affinity for Sm/lGFs or is less abundant. Evidence that the 
BPS in each complex are distinct includes the following find- 
ings: (1) insulin competed with Sm/lGF for binding to the 
45K complex, but not the 40K complex, and (2) the BP in the 
40K complex, but not the 45K complex, was recognized by 
antibodies raised against a BP purified from CM of buffalo 
rat liver (BRL) 3A cells. Growth hormone did not affect the 
apparent secretion of either BP. The binding activity of both 
BPS was retained after mild heat treatment, changes to ex- 
tremes of pH (2-lo), and prolonged storage at -2O”C, but 
was destroyed after heating to higher temperatures (80% 
and greater), reduction, and proteolytic treatment. Neither 
BP appeared to be glycosylated because treatment with en- 
doglycosidase-F resulted in no change in the apparent sizes 
of the complexes or in their capacity to bind Sm/lGFs. Iden- 
tification of the BPS by a modified Western blotting tech- 
nique, involving transfer of electrophoretically separated BPS 
to nitrocellulose membrane and binding with 1Z51-Sm/lGF, re- 
vealed BPS of about 38K and 33K Da, indicating that one 
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molecule of BP bound to one molecule of Sm/lGF. Using the 
BP purified from BRL-3A CM as a surrogate for the 33K 
astroglial BP, we found that it reduced Sm-C/IGF l-stimulated 
3H-thymidine incorporation by astroglial cells in a dose-de- 
pendent manner by binding Sm-C/IGF I and reducing its 
availability to the cell surface receptors. The latter findings 
suggest that the 33K BP may modulate Sm/lGF I’s growth- 
stimulating actions on astroglia. Interactions among Sm/lGFs, 
their binding proteins, and receptors may represent a reg- 
ulatory mechanism for the control of glial growth. 
Somatomedins or insulin-like growth factors (Sm/IGFs) circu- 
late in blood bound to specific binding proteins (BPS) (for re- 
views, see Clemmons and Van Wyk, 198 1; Hintz, 1984; Smith, 
1984; Nissley and Rechler, 1984). In human plasma, 2 major 
forms of Sm/IGF-BP complexes exist: an approximately 150,000 
Da (15OK) species that is under growth hormone (GH) control, 
and a smaller species that is independent of GH and has a 
molecular weight variously estimated to be between 30 and 50K. 
In the rat, similarly sized plasma Sm/IGF-BP complexes are 
observed by gel chromatography (Moses et al., 1976). In both 
human and rat, the GH-independent 30-50K species has been 
shown to be proportionately higher in fetal than in adult plasma 
(D’Ercole et al., 1980; White et al., 1982; Drop et al., 1984b). 
Such Sm/IGF BPS have been demonstrated in human amniotic 
fluid (Chochinov et al., 1977; Bala et al., 1978; Drop et al., 
1979, 1984a; Grizzard et al., 1984), in conditioned media (CM) 
from human fibroblasts (Atkison et al., 1980; Clemmons et al., 
198 1, 1986), liver explants (Rechler et al., 1979; Binoux et al., 
1980) cloned buffalo rat liver (BRL-3A) cells (Moses et al., 
1979; Knauer et al., 1981; Romanus et al., 1986; Mottola et al., 
1986) human hepatoma cells (Moses et al., 1983), fetal mouse 
limb bud explant cultures (D’Ercole et al., 1980) pancreatic 
beta cells (Romanus et al., 1986), and pituitary and brain explant 
cultures (Binoux et al., 1981). These findings suggest hat Sm/ 
IGF BPS are produced by a variety of tissues in vitro and prob- 
ably in vivo. 
The physiological functions of Sm/IGF BPS are unclear. It 
has been suggested that BPS, by virtue of their capacity for 
binding Sm/IGFs, may regulate the release of these peptides at 
their sites of action, and thereby control the biologic function 
of Sm/IGFs (Nissley et al., 1977; Drop et al., 1979; Knauer and 
Smith, 1980; Hintz, 1984). While studying the effects of Sm/ 
IGFs on purified polygonal astroglial cells from neonatal rat 
cerebral cortices, we have identified and characterized 2 distinct 
species of Sm/IGF BP secreted into culture medium by these 
cells. Using a BP purified from CM of BRL-3A cells, which is 
immunologically similar to one of the astroglial BPS character- 
3136 Han et al. - Astroglial Somatomedin Binding Proteins 
ized in this studv. we have shown that the BP inhibits the mi- an additional 0 (2 min), 6, 12, 18, 24, 36, and 48 hr. CM was collected 
and stored frozen at - 20°C. togenic action ofSm/IGFs on astroglial cells by competing with 
the Sm/IGF receptors for Sm/IGF binding. 
Materials and Methods 
Materials. Sm-C/IGF I and IGF II were purified from Cohn fraction 
IV of human plasma, as previously described (Svoboda et al., 1980; 
Svoboda and Van Wyk, 1985). Multiplication-stimulating activity (MSA) 
III-2 was a kind gift of Dr. S. Peter Nissley, NCI, and insulin was a gift 
of Dr. M. Root, from E. Lilly. The peptides were iodinated with NalZSI 
(New England Nuclear, Boston, MA) according to a modification of the 
chloramine-T method (Furlanetto et al., 1977) to specific activities rang- 
ing from 200 to 250 &i/pg. The iodinated Sm-C/IGF I was further 
purified by immunoaffinity chromatography and the other iodinated 
peptides by gel filtration on a Sephadex G-50 column in 1 M acetic acid, 
as previously described (Van Wyk et al., 1980). The iodinated peptides 
were stored in 1 M acetic acid at -70°C and used for the studies within 
2 weeks of iodination. Just prior to use, the iodinated peptides were 
neutralized with 1 M sodium hydroxide to pH 7.0. Human growth 
hormone (hGH) was a gift from Kabi Vitrum (Stockholm, Sweden). 
The Sm/IGF BP was purified from CM of BRL-3A cells, and antibodies 
were raised against it, as previously described (Mottola et al., 1986). 
Both were the generous gift of Dr. Christina Mottola and Michael Czech 
(The University of Massachusetts Medical Center, Worcester, MA). 
~ZSI-Sm/IGFafinitycross-linkingstudies. A modification ofthe meth- 
od described by Wilkins and D’Ercole (1985) was used to affinity cross- 
link 1251-Sm/IGFs to binding proteins in astroglial CM. CM, either un- 
concentrated (50 ~1) or concentrated 110 ~1 of 20 x CM, concentrated 
by centrifugation in Centricon micro~oncentrators (Amicon, Danvers, 
MA) with 10K Da A4, cutoff membrane], was incubated for 30 min with 
1251-Sm-C/IGF I, IGF II, or insulin (250,000 cpm/tube, 100 fmol) in 
100 mM HEPES containing 12 M NaCl, 5 mM KCl, 1.2 mM MgSO,, 
and 8 mr.,r dextrose, pH 7.4 (HEPES buffer) to a final reaction volume 
of 100 ~1 at 4°C with or without varying concentrations of unlabeled 
peptides. Cross-linking was accomplished by the addition of 5 ~1 of 10 
mM disuccinimidyl suberate (DSS; Pierce Chemicals, Rockford, IL) 
dissolved in dimethyl sulfoxide (DMSO) to give a final concentration 
of 0.5 mM DSS. followed by incubation at room temperature for 10 
min. The cross-linking reaction was stopped and the proteins were sol- 
ubilized by the addition of 20 ~1 of 5 x gel sample buffer (62.5 mM Tris- 
HCl, pH 8.8, 5% SDS, 0.0 1% bromophenol blue, and 40% glycerol) 
with or without the reducing agent 2-mercaptoethanol (lO%), and boiled 
for 3 min. 
Affinity cross-linking of 1251-Sm-C/IGF I to receptors on astroglial 
cells was performed as previously described (Han et al., 1987). Briefly, 
purified astroglial cells were plated on 35 mm tissue culture dishes and 
cultured to confluence. The medium was reolaced with SF-BME and 
cultured for another 48 hr. The cells were washed with 100 mM HEPES 
buffer, pH 8.0, with BSA 10 mg/ml, and incubated with 1251-Sm-C/IGF 
I (4-5 x lo5 cpm/dish) in fresh HEPES buffer, without or with varying 
concentrations of BRL-3A BP at 4°C for 16-18 hr. The incubation 
solution was then aspirated, and the cultures were washed 3 times with 
cold HEPES buffer. DH 7.4. without BSA. to remove the unbound 
radiolabel. The 1251-Sm-C/IGF I that was bound to cell surface receptors 
was affinity cross-linked with 0.1 M DSS at 22°C for 10 min. The reaction 
was stopped by aspiration of the DSS solution and addition of 1 ml of 
10 mM Tris-HCl. The cells were scraped from the bottom of the dish 
using a disposable plastic spatula, solubilized in 2% SDS, 12.5 mM Tris- 
HCl, 0.002% bromophenol blue, 8% glycerol, and 100 mM dithiothrietol 
(DTT), and boiled for 5 min. 
Astroglial cultures and collection ofconditioned media. Relatively pure 
cultures of polygonal astroglial cells were prepared from cerebral cortices 
of 1 -d-old Sprague-Dawley rats (Charles River Breeding Laboratories, 
Wilmington, MA), as previously described (McCarthy and de Vellis, 
1980; Han et al., 1987). Briefly, l-d-old rats were decapitated and the 
brains removed aseptically. The cerebral cortices were dissected and the 
meningeal coverings carefully peeled off. The cortical tissue was cut into 
small pieces and incubated in 0.1 O/o trypsin and 0.02% EDTA solution 
(Gibco Laboratories. Grand Island, NY) at room temperature for 30 
min with constant shaking. Trypsin activity was inhibited by the ad- 
dition of twice the volume of basal medium Eagle (BME, Gibco) con- 
taining 10% fetal calf serum (FCS; Hyclone Sterile Systems, Logan, UT). 
The cell suspension was removed and filtered through a 130 pm Nitex 
monofilament screen (Tetko, Elmsford, NY). The remaining tissues 
were triturated mechanically and filtered, the filtrate was combined with 
the initial cell suspension and centrifuged at 2000 x g. The cell pellet 
was gently vortexed and resuspended in complete medium (BME with 
10% FCS, 5 U/ml penicillin, and 5 &ml streptomycin). The number 
of viable cells was determined by the trypan blue-exclusion method in 
a hemacytometer (> 90% viable): A cell-suspension of 2.5-3 x 1 O6 live 
cells/ml was prepared and plated in 200 ml tissue culture flasks (75 cm2 
growth area). The cells were cultured at 37°C in 5% CO, and 95% air 
with 100% humidity for 12-14 d, until confluence. The cells were then 
shaken at 270 rpm for 18 hr at 37”C, and the medium containing 
suspended cells was removed, discarded, and replaced with new com- 
plete medium. The resulting culture consisted of more than 95% flat 
polygonal astroglial cells, as confirmed by phase-contrast microscopy 
and positive immunostaining with the antibody against glial fibrillary 
acid protein (GFAP; McCarthy and de Vellis, 1980). The remaining 
< 5% of cells consisted of process-bearing cells (about half of which were 
astrocytes and half oligodendrocytes), ependymal cells, and fibroblasts. 
Therefore, even though we cannot exclude some contribution towards 
the total BP content of the CM by the nonastrocytic cells, we believe 
that the major portion of the total BP content of the CM was secreted 
by the polygonal astrocytes. 
The samples were then subjected to SDS-PAGE on 6-14% linear 
gradient gels for CM BPS, and 3-14% linear gradient gels for astroglial 
cell membrane receptors, using a Tris-glycine buffer, pH 8.0, according 
to the method of Laemmli (1970). Gels were then fixed in 10% acetic 
acid and 30% methanol solution, washed, dried, and exposed to x-ray 
film (Kodak XAR or XRP) between 2 intensifying screens (DuPont 
Chemical, Wilmington, DE) at -70°C for 3-7 d. The M,s of the stan- 
dards used for SDS-PAGE were myosin (200,000 Da), phosphorylase 
B (97,400 Da), BSA (68,000 Da), ovalbumin (43,000 Da), alpha chy- 
motrypsin (25,700 Da), beta lactglobulin (18,400 Da), and lysozyme 
(14,300 Da) (Bethesda Research Laboratories, Bethesda, MD). 
The cultures were used within 1 week of “purification” and at least 
1 d after the medium change. After purification, cells in 200 ml flasks 
were washed twice with serum-free BME (SF-BME) and incubated in 
20 ml of fresh SF-BME for 24 hr at 37°C. The medium was aspirated 
and replaced with 20 ml of SF-BME containing 2 mg/ml BSA (Sigma, 
lot no. 122F-0890, which contained no Sm-CYIGF I by radioimmu- 
noassay) and incubated at 37°C. CM was collected after 48 hr and stored 
frozen at -20°C. This CM was used for characterization studies. For 
studies of the time course of BP elaboration, astroglial cells were sub- 
plated into 48-well tissue culture plates (1 cm2 growth area/well; Costar, 
Cambridge, MA), at cell densities of 0.12 x 1 O6 cells/well, in BME with 
10% FCS, and cultured until confluence (usually for 48 hr). Cells were 
then washed twice with SF-BME, incubated in fresh SF-BME for 24 hr, 
and then in either SF-BME or SF-BME containing 2 mg/ml BSA for 
Binding of 12SI-Sm-C/IGF I to binding proteins after transfer to ni- 
trocellulose membrane. Concentrated (20 x) astroglial CM, 50 ~1, was 
incubated in 10 ~1 of gel sample buffer 5 times at 50°C for 1 hr and 
the proteins separated on a 6- 14% linear gradient SDS-PAGE, as above. 
This was followed by electrophoretic transfer to nitrocellulose (NC) 
membrane (pore size, 0.45 pm; New England Nuclear, Cambridge, MA) 
on an electrophoretic blotting apparatus (Trans-Blot System; Bio-Rad, 
Richmond, CA) for 500 V hr in Tris-glycine-methanol buffer, pH 7.4. 
After brief washing in this buffer, the NC membrane was air-dried for 
30 min, enclosed in a Micro-Seal plastic bag (Dazey, Industrial Airport, 
KS), and incubated in 0.1 M HEPES buffer, pH 7.4, containing 0.12 M 
NaCl, 5 mM KCl, 1.2 mM MgSO,, 8 mM dextrose, at room temperature 
for 1 hr with constant shaking. This solution was replaced with fresh 
buffer containing 1251-Sm-C/IGF I (0.5 x lo6 cpm/ml) and incubated 
at room temperature for 1 hr. The NC membrane was removed from 
the bag and washed thoroughly with Tris-saline buffer containing 0.02% 
Nonidet-P 40 (Sigma) for 2 hr, with several changes of wash buffer, 
until the buffer was devoid of radiolabel. The NC membrane was air- 
dried for 30 min and exposed to x-ray film (Kodak XRP-5) at -70°C 
for 4-8 hr. A similar technique has been used to analyze Sm/IGF BPS 
in human serum (Hossenlopp et al., 1986). 
Immunoprecipitation of afinity-labeled BPS. Ten microliters of 20 x 
concentrated CM in 10 mM HEPES buffer was affinity-labeled with 1251- 
Sm-C/IGF I, as described above (final reaction vol, 100 ~1). To this 
solution, 25 ~1 of BRL-3A antibodies (F or P) or control preimmune 
antibody (C) was added to achieve a final dilution of 1: 100 and incubated 
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at 4°C for 18-20 hr (the antibodies were partially purified by precipi- 
tating antisera with 30% ammonium sulfate, and followed by dialysis 
and lyophilization). Sheep anti-rabbit antiserum (15 & Wellcome Lab- 
oratories, Beckinham, UK) was added to each sample and incubated 
for another 2 hr at room temperature. Finally, 10 ~1 of normal rabbit 
serum was added to each sample and incubated for 2 hr at 4°C. Im- 
munoprecipitates were collected by centrifugation in a microcentrifuge 
for 5 min and washed twice with phosphate buffer, pH 7.4. Immuno- 
precipitates were solubilized in 50 ~1 gel sample buffer (62.5 mM Tris- 
HCl, pH 6.8, 1% SDS, 8% glycerol, 0.1% bromophenol blue, and 2% 
2-mercaptoethanol) and boiled for 3 min. Samples were subjected to 
6-14% linear gradient SDS-PAGE and the gels were fixed, dried, and 
autoradiographed as described above. 
Astroglial receptor binding studies. Binding studies were performed 
on plated astroglial cells as previously described (Han et al., 1987). 
Briefly, astroglial cells were plated on 48-well tissue culture plates and 
cultured until confluence. They were then incubated in SF-BME for 48 
hr prior to incubation with lZSI-Sm-C/IGF I (50,000 cpm/well; 20 fmol) 
in 0.1 M HEPES binding buffer, pH 8.0, in the presence of graded 
concentrations of BRL-3A BP (5 @ml to 1 &ml) for 4 hr at 4°C. 
Nonspecific binding was determined as binding in the presence of an 
excess of unlabeled Sm-C/IGF I (10 &ml). Binding was terminated by 
aspiration of the incubating solution and washing the cultures thor- 
oughly with cold PBS 3 times. The cells were solubilized with 0.1 N 
NaOH and 1% SDS for 15 min at room temperature, and the cell lysate 
was transferred to test tubes. The cell associated radioactivity was then 
determined in a gamma spectrometer (Hewlett-Packard, Corvallis, OR). 
‘H-Thymidine incorporation studies. The effects of BRL-3A BP on 
the mitogenic action of Sm-C/IGF I on astroglial cells was determined 
by ‘H-thymidine incorporation assay, as previously described (Han et 
al., 1987). Briefly, astroglial cells were plated on 48-well tissue culture 
plates and cultured to subconfluence (usually 48 hr). They were then 
incubated in SF-BME for 48 hr and exposed to 25 rig/ml Sm-C/IGF I 
with varying concentrations of the BRL-3A BP (O-l &ml). After in- 





Figure 1. Electrophoretic analysis and 
autoradiography of 1251-Sm-C/IGF I BP 
complexes in astroglial CM cross-linked 
in the absence and presence of unla- 
beled Sm-C/IGF I, IGF II, or insulin. 
Lefl, indication of the migration of M, 
markers (x lo-‘). The 45K complex 
(large arrow) and 40K complex (small 
arrow) are diminished in intensity or 
obliterated in the presence of unlabeled 
Sm-C/IGF I (B-E) and IGF II (F-r). 
Unlabeled insulin at 10 &ml dimin- 
ished the intensity of the 45K complex 
but not the 40K complex (J). A ra- 
diolabeled band of approximately 68K 
observed in each lane represents a non- 
specific binding of ‘251-Sm-C/IGF I to 
albumin in the CM. 
was added to the cultures and the incubation was continued for another 
2 hr. The reaction was stopped by aspiration of the incubating solution 
and washing with cold (4oC) PBS 3 times. The cultures were then in- 
cubated with 5% trichloracetic acid (TCA) at 4°C for 20 min. The TCA 
solution was aspirated and the cultures were washed again with fresh 
5% TCA. After removal of the TCA solution, the cultures were solu- 
bilized in 0.1 N NaOH and 1% SDS. The resulting solution was added 
to 10 ml of complete counting cocktail (Research Products International, 
Elk Grove Village, IL) and counted in a scintillation counter (LKB 
Instruments, Gaithersburg, MD). 
Results 
Afinity-labeled SmLGF-BP complexes in astroglial CA4 
When concentrated astroglial CM was affinity-labeled with lZ51- 
Sm-C/IGF I and analyzed by SDS-PAGE, 2 species of radiola- 
beled Sm-C/IGF I-BP complexes, with M,s of 45K and 40K 
were observed under reducing conditions (Fig. 1). Under non- 
reducing conditions, 2 similar-sized species were observed, but 
the resolution of the 2 bands was inferior (not shown). These 
bands were judged to represent specific Sm/IGF-BP complexes 
because their intensity was diminished or obliterated when either 
unlabeled Sm-C/IGF I or IGF II (50 rig/ml) was present during 
the incubation. The 45K complex could be lessened in intensity 
by as little as 5 r&ml Sm-C/IGF I (not shown) or 10 r&ml IGF 
II, and obliterated by 20 rig/ml Sm-C/IGF I or 50 r&ml IGF 
II. Very high concentrations of insulin (10 &ml) could also 
compete for lZSI-Sm-C/IGF I binding. Approximately IO-fold 
higher concentrations of either Sm-C/IGF I or IGF II were 
required to compete for the binding in the 40K complex, while 
10 &ml of insulin did not appear to compete for this binding. 
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Figure 2. Electrophoreticanalysis and 
autoradiography of lZSI-IGF II BP com- 
plexes in astroglial CM cross-linked in 
the absence and presence of unlabeled 
IGF II, Sm-C/IGF I, or insulin. L$, 
indication ofthe migration ofM, mark- 
ers (x lO-3). The 45K complex (large 
arrow) and 40K complex (small arrow) 
are diminished in intensity in the pres- 
ence of unlabeled IGF II (B-E) and Sm- 
C/IGF I (F-I). Unlabeled insulin at 10 
pg/ml diminished the intensity of the 
45K complex, but not of the 4dK com- 
plex Q. A radiolabeled band of ap- 
proximately 68K observed in each lane 
represents a nonspecific binding of 12sI- 
Sm-C/IGF I to albumin in the CM. 
B C D E 
The BP represented in the 45K complex, therefore, appears 
either to have a higher affinity for Sm/IGFs or to be less abun- 
dant than that in the 40K complex. A cross-linked band of M, 
about 68K was also radiolabeled, and represents nonspecific 
binding of radiolabeled Sm/IGF to the albumin contained in 
the medium (Wilkins and D’Ercole, 1985). 
When astroglial CM was affinity cross-linked to lz51-IGF II, 
2 identically sized protein bands were radiolabeled (Fig. 2). 
These bands were nearly obliterated by incubation with 50 ng/ 
ml of unlabeled IGF II or Sm-C/IGF I. As with binding to L251- 
Sm-C/IGF I, low concentrations of unlabeled Sm/IGFs (10 ng/ 
ml) obliterated the 45K complex, while Sm/IGF concentrations 
of 50-100 rig/ml were required to obliterate the 40K complex. 
Unlabeled Sm-C/IGF I was equipotent to unlabeled IGF II in 
competing with radiolabeled IGF II for both binding proteins. 
As with 1251-Sm-C/IGF I binding, unlabeled insulin at very high 
concentrations (10 pg/ml) diminished the intensity of the 45K 
complex, but had no apparent effect on the 40K complex. 
Afinity-labeled 1Z51-insulin-BP complexes in astroglial CM 
When 1251-insulin was used as a radiolabel for affinity cross- 
linking with astroglial CM, a single 45K band of relatively low 
intensity was radiolabeled (Fig. 3). The BP in this complex 
appeared to have a low affinity for L2SI-insulin because 10 pg/ 
ml of unlabeled insulin was required to diminish its intensity. 
There was no apparent competition with either Sm-C/IGF I or 
IGF II at concentrations of 100 @ml, suggesting that insulin 
was not bound to the same site as the Sm/IGFs. 
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Studies of BP secretion 
CM collected by incubation of astroglial cells in SF-BME for 
48 hr resulted in a decrease in the intensity of radiolabeled 
complexes, as compared to CM collected by incubation of as- 
troglia with SF-BME containing BSA (data not shown). The 
latter finding suggests that BP synthesis is dependent on an 
exogenous protein source. To study the time course of secretion 
of the BPS, astroglial cultures were serum-starved for 48 hr, then 
incubated with SF-BME with BSA and CM collected at 6 hourly 
intervals. When CM were affinity cross-linked to ‘ZSI-Sm-C/IGF 
I, both complexes were detectable at 6 hr, and progressively 
increased in apparent abundance. The 40K complex was more 
intensely labeled than the 45K complex at each time, suggesting 
that it is more rapidly synthesized and therefore more abundant. 
Incubation with hGH did not alter the apparent rate of synthesis 
of either BP. 
Biochemical characteristics of the BPS 
To further characterize these BPS, they were subjected to a va- 
riety of physicochemical treatments prior to affinity cross- 
linking with L251-Sm-C/IGF I. Heating of CM to 56°C for 2 hr, 
freezing at -20°C for up to 3 months, acidification (to pH 2), 
alkalinization (to pH lo), or incubation with endoglycosidase-F 
(l-l 00 U/ml; New England Nuclear) did not have apparent 
effects on L251-Sm-C/IGF I binding or on the size of the binding 
moieties. However, heating at temperatures of 80°C or higher 
for 5 min, reduction with 2-mercaptoethanol, and mild pro- 
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teolytic treatment (e.g., 0.001% trypsin for 30 min) destroyed 
binding activity. These results are consistent with pH-stable, 
nonglycosylated proteins, which contain interchain disulfide 
bonds that are essential for binding. 
Binding of 1251-Sm-C/IGF I to BPS transferred to 
nitrocellulose membrane 
After transfer of electrophoretically resolved astroglial CM to 
nitrocellulose membrane and binding with 1251-Sm-C/IGF I, 2 
radiolabeled bands with A4,s of 38-4OK and 33-35K were ob- 
served. These bands appear to represent the 45 and 43K BP 
complexes that were observed when conditioned medium was 
affinity cross-linked to 1251-Sm-C/IGF I prior to separation on 
SDS-PAGE (Fig. 4). Because the M,s of the BPS thus identified 
correspond well with those of the affinity-labeled complexes 
minus the J4, of the radiolabeled ligand (45K - 7K = 38K, and 
40K - 7K = 33K), these findings are consistent with the binding 
of a single molecule of Sm/IGF to each BP molecule. 
Relationship between astroglial BPS and BRL-3A BP 
Affinity labeling of the BP purified from BRL-3A cells with lzsI- 
Sm-UIGF I revealed a single band of AJ, 40K, which could be 
obliterated by incubation with 100 rig/ml of unlabeled Sm-C/ 
IGF I (Fig. 7). When astroglial BP was affinity-labeled with L2sI- 
Sm-C/IGF I and immunoprecipitated with antisera F and P, 
which were raised against BRL-3A BP, a single band of M, 40K 
was observed (Fig. 5). A control preimmune rabbit serum (C) 
50 
Figure 3. Electrophoreticanalysis and 
autoradiography of W-insulin BP 
complexes in astroglial CM cross-linked 
in the absence and presence of unla- 
beled insulin (B, c), unlabeled Sm-C/ 
IGF I (0, E) and unlabeled IGF II (F, 
G). Left. indication of the migration of 
M, markers (x lo-‘). A single radiola- 
beled band of 4X (large arrow) is ob- 
served and is diminished in intensity 
only by a high concentration of unla- 
beled insulin (10 p&ml; C’). Sm-C/IGF 
I and IGF II in the concentrations used 
have no apparent effect. 
WGF II-’ 
did not result in positive immunoprecipitation. These results 
demonstrate that the BRL-3A BP is immunologically similar 
to the rat astroglial BP in the 40K complex. 
Eflects of BRL-3A BP on the mitogenic action of Sm-UIGF I 
Addition of 25 rig/ml Sm-C/IGF I stimulates 3H-thymidine 
incorporation of astroglial cells 4-fold above the basal condi- 
tions. 3H-Thymidine incorporation could be reduced by purified 
BRL-3A BP in a dose-dependent manner (Fig. 6). Addition of 
BRL-3A BP to astroglial cells in the absence of Sm-C/IGF I did 
not alter the basal 3H-thymidine incorporation, suggesting that 
the effect of the BP is specific to the mitogenic action of Sm-CI 
IGF I on astroglia. 
To determine whether the effect of BP on the mitogenic action 
of Sm-C/IGF I was due to competition with the Sm/IGF re- 
ceptors for the peptide, increasing concentrations of the BP were 
added to a constant concentration of radiolabeled Sm-C/IGF I. 
The BRL-3A BP inhibited 1251-Sm-C/IGF I binding to astroglial 
cells in a dose-dependent manner (Fig. 7). Moreover, the BP 
concentration causing half-maximal binding inhibition (77 ng/ 
ml) was nearly identical to the concentration resulting in half- 
maximal inhibition of mitogenic response to Sm-C/IGF I (80 
rig/ml). These findings strongly suggest that the BRL-3A BP 
inhibits the mitogenic actions of Sm-CYIGF I by competing with 
the receptor for the ligand. 
The latter conclusion is further supported by the affinity cross- 
linking studies. Affinity-labeling of the astroglial cell surface 





Figure 4. Identification of astroglial Srn/IGF BPS by transfer to nitro- 
cellulose membrane following electrophoresis and binding to 12’I-Sm- 
UIGF I (B). BPS identified by the affinity cross-linking method are 
shown in A for comparison. Left, indication of migration of M, markers 
(x 10-J). 
receptors with 1251-Sm-C/IGF I and analysis on SDS-PAGE 
under reducing conditions (Fig. 8) showed radiolabeled bands 
of M, 130K (alpha subunit of the type I Sm/IGF receptor), A4, 
260K (type II Sm/IGF receptor) and M, > 300K (unreduced 
type I receptor). Specificity of binding of the radiolabel to these 
receptors has been shown previously (Han et al., 1987). The 
addition of increasing concentrations of BRL-3A BP to the bind- 
ing buffer prior to cross-linking diminished the intensity of all 
3 bands, and at BP concentration of 1 &ml, radiolabeled re- 
ceptor complexes were not observed (Fig. 8). The reduction in 
the intensity of radiolabeled bands in the presence of increasing 
concentrations of BP correlated well with the inhibition of spe- 
cific binding observed in the binding studies (Fig. 7). These 
results indicate that the BP binds Sm-C/IGF I and prevents 
binding of Sm-C/IGF I to its cell surface receptors. Sm-C/IGF 
I is thus rendered biologically inactive. Similar findings were 
observed with radiolabeled IGF II (data not shown). 
Discussion 
By using DSS, we have covalently cross-linked radiolabeled Sm/ 
IGFs to specific binding moieties in CM from rat astroglial cells. 
Our evidence suggests that each is a pH-stable, nonglycosylated 
protein with interchain disulfide linkages capable of binding one 
molecule of either Sm-C/IGF I or IGF II with near-equal affin- 
ity. The BPS in these cross-linked complexes appear to have 
M,s of 38-40K and 33-35K Da, respectively. 
Both Sm-UIGF I and IGF II (or MSA) appeared equipotent 
in competing for the binding to each of the BPS, suggesting that 
the Sm/IGFs share the same BPS. This is in agreement with our 
previous findings of rat serum BPS (D’Ercole and Wilkins, 1984), 
as well as those of Moses et al. (1976). That the 45K complex 
was about 5-fold more sensitive to competition by the Sm/IGFs 
than the 40K complex may reflect either differences in affinity 
or in the abundance of each BP. The techniques used do not 
distinguish between these possibilities. 
Several lines of evidence indicate that the 45 and the 40K 
complexes represent distinct BPS: (1) The 40K cross-linked 
complex, but not the 45K complex, is recognized by antibodies 
against the BRL-3A BP. (2) The BP in the 45K complex rec- 
ognizes insulin weakly, while that in the 40K complex does not. 
(3) Because endoglycosidase-F did not decrease the size of either 
complex, it is. unlikely that the BP in the 45K complex is a 
N-glycosylated form of the 40K species. And (4), our finding 
that the 2 BPS could be separated electrophoretically prior to 
binding with a radiolabeled ligand indicates that the 2 complexes 
do not represent the same BP bound to different numbers of 
Sm/IGF molecules. 
Sm/IGF BPS of sizes similar to those observed here have been 
identified in rat serum both by column chromatography (Moses 
et al., 1976) and affinity cross-linking (D’Ercole and Wilkins, 
1984). The 40K complex we observed appears similar or iden- 
tical to the non-GH-dependent 40K complex observed in rat 
serum. This BP was recognized by antibodies raised against a 
32K BP purified from BRL-3A cells (Mottola et al., 1986). 
Romanus et al. (1986) also purified a BP of near-identical size 
(33K) from BRG3A CM, and showed that antibodies raised 
against it recognized the 40K non-GH-dependent BP complex 
in rat serum. Our finding that the 40K complex elaborated by 
astroglial cells is not increased in apparent abundance by in- 
cubation with GH further supports our conclusion that the 33- 
35K BP in this complex is the same or very similar to the blood- 
borne non-GH-dependent BP. 
The identity of the 45K complex is less clear. We have ob- 
served a similarly sized (49K) Sm/IGF-BP complex by affinity 
cross-linking of rat serum (D’Ercole and Wilkins, 1984). Our 
finding that the BP represented in this species can bind insulin 
(albeit with low affinity) argues that this BP is unique, because, 
to our knowledge, no other Sm/IGF BP has been reported as 
recognizing insulin even at high concentrations. Gjedde (1967), 
however, has reported that insulin binds to cat serum proteins 
that migrate at a similar molecular size on open-bed columns. 
The very low apparent affinity of the BP in the 45K complex 
makes it unlikely to function as a circulating carrier of insulin. 
The tissue culture technique we used results in a relatively 
pure (> 90%) population of polygonal astroglial cells by mor- 
phological and immunocytochemical criteria (McCarthy and de 
Vellis, 1980), and thus provides evidence that the BPS char- 
acterized in this study were synthesized by these cells. However, 
we cannot exclude the contribution of other nonastrocytic cells, 
e.g., fibroblasts, oligodendrocytes, and ependymal cells, which 
form less than 5% of the cells. The confirmation of the presence 
of cell types that produce these BPS awaits in situ hybridization 
analysis with specific IGF BP cDNA probes. Further evidence 
of synthesis comes from the findings that there is an apparent 
reduction in BP following serum starvation, and an apparent 
progressive increase in BP when cells are incubated in SF-BME 









with BSA. Our findings agree with those of Binoux et al. (198 l), 
who found that similarly sized BPS (as judged by open-bed gel 
chromatography) were synthesized by mixed neural cells in cul- 
ture. On the basis of the affinity of BPS to IGFs and insulin, it 
Figure 6. Reduction of 3H-thymidine incorporation of astroglial cells 
in response to Sm-UIGF I (25 @ml) in the presence of increasing 
concentrations of BRL-3A BP. Each point is a mean f SEM of 6 
replicates. Sm-C/IGF I, 25 rig/ml, increases ‘H-thymidine incorporation 
4-fold under control conditions. The presence of increasing concentra- 
tions of BRL-3A BP in the absence of Sm-CYIGF I does not alter basal 
‘H-thymidine incorporation of astroglial cells (data not shown). The 
concentration of BRG3A BP that caused half-maximal reduction of 
‘H-thymidine incorporation of astroglia was 80 @ml. 
Figure 5. Electrophoretic analysis and 
autoradiography of the cross-linked lZsI- 
Sm-UIGF I BRL-3A BP complexes in 
the absence (B) and presence of 100 ng/ 
ml unlabeled Sm-CYIGF I (c). Binding 
protein complexes in astroglial CM is 
shown in A for comparison. Electro- 
phoretic analysis and autoradiography 
of L2SI-Sm-C/IGF I BP complexes in as- 
troglial CM immunoprecipitated with 
preimmune serum C (0) and antibodies 
F and P raised against BRL-3A BP (E, 
F). Lefi, indication of migration of M, 
markers (x 10-3). 
is possible that the 45K complex, and not the 40K complex, 
could be derived by limited proteolysis of the IGF receptor(s). 
Recently, Kiess et al. (1987), using immunologic and affinity 
cross-linking techniques, have shown that type II IGF receptor 
Bindlng Protein (nglml) 
Figure 7. Competition for 1251-Sm-C/IGF I binding to astroglial cells 
by increasing concentrations of BRL-3A BP. Nonspecific binding is 
binding in the presence of 10 pg/ml of unlabeled Sm-C/IGF I. Each 
point is a mean of 3 replicates. Maximum specific binding of lZ51-Sm- 
C/IGF I to astroglial cells under control conditions (absence of BRL- 
3A BP) is approximately 10%. The concentration of BRL-3A BP that 
caused half-maximal reduction of specific binding to astroglial cells was 
77 rig/ml. 
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Figure 8. Electrophoretic analysis and autoradiography of alfmity cross- 
linked i251-Sm-C/IGF I bound astroglial cell surface receptors in the 
absence (A) and presence (B-O) of increasing concentrations of BRL- 
3A BP (under reducing conditions). Le#, indication of migration of M, 
markers (X 10-3). Arrows indicate affinity-labeled cell surface receptors. 
can be detected by radioimmunoassay in the serum of rats. The 
level of type II receptor appears to be developmentally regulated. 
The sizes of the binding moieties are 2 10 and 240 kDa under 
nonreduced and reduced conditions, respectively, and, there- 
fore, are consistent with the sizes of the cell surface receptors 
under similar conditions. However, they are different from the 
sizes of the astroglial BPS described in this study. 
Our data clearly demonstrate that addition of the BRL-3A 
BP to astroglia inhibits the action of Sm-C/IGF I by preventing 
Sm-C/IGF I binding to its cell surface receptors. Because this 
BP is similar to the 33K species elaborated by astroglia, we 
assume that the latter would exert the same effect. Other influ- 
ences of BP, however, seem possible. Elgin et al. (1987) have 
recently shown that a 35K BP purified from human amniotic 
fluid can potentiate the mitogenic action of Sm-C/IGF I in 
cultured fibroblasts, possibly by delivering Sm-C/IGF I to its 
cell surface receptors. We have shown that human fibroblasts 
secrete a BP of approximately 35K Da that associates with the 
cell surface and modulates the abundance of Sm-C/IGF I on 
the cell surface, including Sm-C/IGF I receptor binding (Clem- 
mons et al., 1986). Using identical procedures, however, we did 
not observe rat astroglial BPS to be associated with the astroglial 
cell surface (unpublished observation). It seems possible that 
BPS that are secreted into the media have different effects than 
those capable of associating with the cell surface. 
Herein, we have shown that neonatal rat astroglia secrete 
binding proteins that may modulate the biologic actions of Sml 
IGFs. Binoux et al. (198 1) have shown that pituitary and brain 
explants produce Srn/IGFs. Specific Sm/IGF receptors have been 
demonstrated on neuronal (Burgess et al., 1987) and glial (Han 
et al., 1987) cells, and astroglia and oligodendroglia have been 
shown to respond to the mitogenic actions of Sm/IGFs (McMorris 
et al., 1986; Han et al., 1987). Taken together, these data point 
to a role for the Sm/IGFs in the development of glial cells. The 
present study is consistent with this hypothesis and suggests that 
the regulation of growth of glial cells may involve a complex 
mechanism of interactions between Sm/IGFs, their receptors 
and BPS. 
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